Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Insurance coverage and consistent pricing is needed for over-the-counter naloxone.
J Opioid Manag
January 2025
Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill; South East Area Health Education Center, College of Nursing, University of North Carolina Wilmington, Wilmington, North Carolina. ORCID: https://orcid.org/0000-0002-7507-0631.
With the Food and Drug Administration's approval of the first over-the-counter naloxone nasal spray in 2023, it was expected that access to naloxone nasal spray would increase and that its cost would be reduced. However, the writers of this commentary found varying insurance coverage of naloxone during purchase attempts at local pharmacies. Failure to cover naloxone can reduce access and increase risk of overdose death.
View Article and Find Full Text PDFEvidence-based clinical practice guidelines for the management of acute dental pain.
Am J Emerg Med
December 2024
Center for Integrative Global Oral Health, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Objective: In the United States, on average, every 15 s, someone visits a hospital emergency department (ED) for a dental condition. This commentary summarizes the recommendations from a 2024 clinical practice guideline for the pharmacological management of acute dental pain associated with tooth extractions and toothache applicable to ED settings, hospitals, and urgent care clinics where definitive dental treatment is not immediately available.
Methods: A guideline panel convened by the American Dental Association, the ADA Science & Research Institute, the University of Pittsburgh School of Dental Medicine, and Penn Dental Medicine examined the effect of opioid and non-opioid analgesics; local anesthetics, including blocks; corticosteroids; and topical anesthetics on acute dental pain.
Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.
Br J Psychiatry
November 2024
Medical & Scientific Affairs, Janssen-Cilag Pty Ltd, Sydney, Australia.
Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial', we commend Loo et al for undertaking the Ketamine for Adult Depression Study (KADS). In the interest of ensuring that accurate and balanced information is presented to healthcare professionals on treatment-resistant depression, we raise several points herein to help clarify and provide additional perspective to the researchers' interpretation of their findings in the Discussion.
View Article and Find Full Text PDFA decade of pyridine-containing heterocycles in US FDA approved drugs: a medicinal chemistry-based analysis.
RSC Med Chem
October 2024
Department of Pharmaceutical Sciences, Chauras Campus, HNB Garhwal University (A Central University) Srinagar Uttarakhand 246174 India
Heterocyclic scaffolds, particularly, pyridine-containing azaheterocycles, constitute a major part of the drugs approved in the past decade. In the present review, we explored the pyridine ring part of US FDA-approved small molecules (2014-2023). The analysis of the approved drugs bearing a pyridine ring revealed that a total of 54 drugs were approved.
View Article and Find Full Text PDFWhat Psychiatrists Should Know About Prescribed Safer Opioid Supply.
Can J Psychiatry
November 2024
Department of Psychiatry, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
What Psychiatrists Should Know About Prescribed Safer Opioid Supply.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!